{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:10:51Z","timestamp":1791587451091,"version":"4.3.4"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10600-y","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:27:24Z","timestamp":1773034044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intensive blood pressure control in heart failure with preserved ejection fraction: a symptom-modifying strategy"],"prefix":"10.1007","volume":"31","author":[{"given":"Muhammad Sameer","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-2357","authenticated-orcid":false,"given":"Muhammad","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Philipp","family":"Rommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert D.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh V.","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Antonio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"17","key":"10600_CR1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2022","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2022) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10600_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","volume":"31","author":"B Bozkurt","year":"2025","unstructured":"Bozkurt B et al (2025) HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America. J Card Fail 31(1):66\u2013116. https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.001","journal-title":"J Card Fail"},{"issue":"10","key":"10600_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65","journal-title":"Nat Rev Cardiol"},{"key":"10600_CR4","doi-asserted-by":"publisher","unstructured":"Tsioufis C et al (2017) Hypertension and heart failure with preserved ejection fraction: connecting the Dots. Curr Vasc Pharmacol 16(1). https:\/\/doi.org\/10.2174\/1570161115666170414120532","DOI":"10.2174\/1570161115666170414120532"},{"issue":"2","key":"10600_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/nejmcp2305181","volume":"392","author":"A Cannata","year":"2025","unstructured":"Cannata A, McDonagh TA (2025) Heart failure with preserved ejection fraction. N Engl J Med 392(2):173\u2013184. https:\/\/doi.org\/10.1056\/nejmcp2305181","journal-title":"N Engl J Med"},{"issue":"20","key":"10600_CR6","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","volume":"275","author":"D Levy","year":"1996","unstructured":"Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK (1996) The progression from hypertension to congestive heart failure. JAMA 275(20):1557\u20131562","journal-title":"JAMA"},{"issue":"1","key":"10600_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43044-025-00622-6","volume":"77","author":"MS Arshad","year":"2025","unstructured":"Arshad MS et al (2025) Trends in hypertensive heart disease-related mortality among older adults in the USA: a retrospective analysis from CDC WONDER between 1999 and 2020. Egypt Heart J EHJ Off Bull Egypt Soc Cardiol 77(1):27. https:\/\/doi.org\/10.1186\/s43044-025-00622-6","journal-title":"Egypt Heart J EHJ Off Bull Egypt Soc Cardiol"},{"key":"10600_CR8","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.15420\/cfr.2022.06","volume":"8","author":"K Teramoto","year":"2022","unstructured":"Teramoto K, Teng T-H, Chandramouli C, Tromp J, Sakata Y, Lam CS (2022) Epidemiology and clinical features of heart failure with preserved ejection fraction. Card Fail Rev 8:e27. https:\/\/doi.org\/10.15420\/cfr.2022.06","journal-title":"Card Fail Rev"},{"issue":"1","key":"10600_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"Authors\/Task Force Members: et al","year":"2024","unstructured":"Authors\/Task Force Members: et al et al (2024) 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 26(1):5\u201317. https:\/\/doi.org\/10.1002\/ejhf.3024","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10600_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM et al (2023) 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. JACC 81(18):1835\u20131878. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.393","journal-title":"JACC"},{"key":"10600_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","volume":"26","author":"GC Oh","year":"2020","unstructured":"Oh GC, Cho H-J (2020) Blood pressure and heart failure. Clin Hypertens 26:1. https:\/\/doi.org\/10.1186\/s40885-019-0132-x","journal-title":"Clin Hypertens"},{"issue":"8","key":"10600_CR12","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","volume":"39","author":"A Kasiakogias","year":"2021","unstructured":"Kasiakogias A et al (2021) Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. J Hypertens 39(8):1522. https:\/\/doi.org\/10.1097\/HJH.0000000000002910","journal-title":"J Hypertens"},{"key":"10600_CR13","doi-asserted-by":"publisher","unstructured":"Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ (2020) Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis 63(1):10\u201321. https:\/\/doi.org\/10.1016\/j.pcad.2019.11.009","DOI":"10.1016\/j.pcad.2019.11.009"},{"issue":"9","key":"10600_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA (2014) The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 11(9):507\u2013515. https:\/\/doi.org\/10.1038\/nrcardio.2014.83","journal-title":"Nat Rev Cardiol"},{"issue":"30","key":"10600_CR15","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP de Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 39(30):2780\u20132792. https:\/\/doi.org\/10.1093\/eurheartj\/ehy301","journal-title":"Eur Heart J"},{"issue":"9","key":"10600_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS et al (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8(9):712\u2013724. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10600_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","volume":"117","author":"L van Heerebeek","year":"2008","unstructured":"van Heerebeek L et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117(1):43\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.728550","journal-title":"Circulation"},{"issue":"2","key":"10600_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s0008-6363(99)00099-1","volume":"43","author":"AF Leite-Moreira","year":"1999","unstructured":"Leite-Moreira AF, Correia-Pinto J, Gillebert TC (1999) Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 43(2):344\u2013353. https:\/\/doi.org\/10.1016\/s0008-6363(99)00099-1","journal-title":"Cardiovasc Res"},{"issue":"9579","key":"10600_CR19","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/S0140-6736(07)60980-5","volume":"369","author":"SD Solomon","year":"2007","unstructured":"Solomon SD et al (Jun. 2007) Effect of angiotensin receptor Blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369:2079\u20132087. https:\/\/doi.org\/10.1016\/S0140-6736(07)60980-5","journal-title":"Lancet"},{"issue":"12","key":"10600_CR20","doi-asserted-by":"publisher","first-page":"e010673","DOI":"10.1161\/CIRCHEARTFAILURE.123.010673","volume":"16","author":"M Tamargo","year":"2023","unstructured":"Tamargo M et al (2023) Increased chamber resting tone is a key determinant of left ventricular diastolic dysfunction. Circ Heart Fail 16(12):e010673. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010673","journal-title":"Circ Heart Fail"},{"key":"10600_CR21","doi-asserted-by":"publisher","unstructured":"Haykal R, Kassar A, Chamoun N, Akoum N (2025) The left atrium in heart failure with preserved ejection fraction: what we know and what we do not know. Heart Rhythm O2. https:\/\/doi.org\/10.1016\/j.hroo.2025.04.007","DOI":"10.1016\/j.hroo.2025.04.007"},{"key":"10600_CR22","doi-asserted-by":"publisher","unstructured":"Ovchinnikov A, Belyavskiy E, Potekhina A, Ageev F (2022) Asymptomatic left ventricular hypertrophy is a potent risk factor for the development of HFpEF but not HFrEF: results of a retrospective cohort study. J Clin Med 11(13):3885. https:\/\/doi.org\/10.3390\/jcm11133885","DOI":"10.3390\/jcm11133885"},{"key":"10600_CR23","doi-asserted-by":"publisher","unstructured":"R. S et al (2022) Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation 146(7). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059280","DOI":"10.1161\/CIRCULATIONAHA.122.059280"},{"key":"10600_CR24","doi-asserted-by":"publisher","unstructured":"Rommel K-P et al (2016) Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 67(15):1815\u20131825. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.018","DOI":"10.1016\/j.jacc.2016.02.018"},{"key":"10600_CR25","doi-asserted-by":"publisher","unstructured":"Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction. Circulation 107(5):714\u2013720. https:\/\/doi.org\/10.1161\/01.CIR.0000048123.22359.A0","DOI":"10.1161\/01.CIR.0000048123.22359.A0"},{"key":"10600_CR26","doi-asserted-by":"publisher","unstructured":"Martinez-Quinones P et al (2018) Hypertension induced morphological and physiological changes in cells of the arterial wall. Am J Hypertens 31(10):1067\u20131078. https:\/\/doi.org\/10.1093\/ajh\/hpy083","DOI":"10.1093\/ajh\/hpy083"},{"key":"10600_CR27","doi-asserted-by":"publisher","unstructured":"Kim H-L (2023) Arterial stiffness and hypertension. Clin Hypertens 29(31). https:\/\/doi.org\/10.1186\/s40885-023-00258-1","DOI":"10.1186\/s40885-023-00258-1"},{"issue":"43","key":"10600_CR28","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1093\/eurheartj\/ehy346","volume":"39","author":"T Weber","year":"2018","unstructured":"Weber T, Chirinos JA (2018) Pulsatile arterial haemodynamics in heart failure. Eur Heart J 39(43):3847\u20133854. https:\/\/doi.org\/10.1093\/eurheartj\/ehy346","journal-title":"Eur Heart J"},{"issue":"6","key":"10600_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/01.HYP.0000128420.01881.aa","volume":"43","author":"GF Mitchell","year":"2004","unstructured":"Mitchell GF et al (2004) Changes in arterial stiffness and wave reflection with advancing age in healthy men and women. Hypertension 43(6):1239\u20131245. https:\/\/doi.org\/10.1161\/01.HYP.0000128420.01881.aa","journal-title":"Hypertension"},{"issue":"4","key":"10600_CR30","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ehf2.14422","volume":"10","author":"D Ali","year":"2023","unstructured":"Ali D et al (2023) Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction. ESC Heart Fail 10(4):2487\u20132498. https:\/\/doi.org\/10.1002\/ehf2.14422","journal-title":"ESC Heart Fail"},{"key":"10600_CR31","doi-asserted-by":"publisher","unstructured":"Juilli\u00e8re Y, Venner C, Filippetti L, Popovic B, Huttin O, Selton-Suty C (2018) Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options. Arch Cardiovasc Dis 111(12):766\u2013781 https:\/\/doi.org\/10.1016\/j.acvd.2018.04.007","DOI":"10.1016\/j.acvd.2018.04.007"},{"issue":"1","key":"10600_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","volume":"115","author":"K Sharma","year":"2014","unstructured":"Sharma K, Kass DA (2014) Heart failure with preserved ejection fraction. Circ Res 115(1):79\u201396. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.302922","journal-title":"Circ Res"},{"issue":"5","key":"10600_CR33","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1161\/HYPERTENSIONAHA.112.202705","volume":"60","author":"SL Hummel","year":"2012","unstructured":"Hummel SL et al (2012) Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60(5):1200\u20131206. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.202705","journal-title":"Hypertension"},{"issue":"12","key":"10600_CR34","doi-asserted-by":"publisher","first-page":"100705","DOI":"10.1016\/j.xkme.2023.100705","volume":"5","author":"RN Patel","year":"2023","unstructured":"Patel RN, Sharma A, Prasad A, Bansal S (2023) Heart failure with preserved ejection fraction with CKD: A narrative review of a multispecialty disorder. Kidney Med 5(12):100705. https:\/\/doi.org\/10.1016\/j.xkme.2023.100705","journal-title":"Kidney Med"},{"issue":"8","key":"10600_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/CIRCULATIONAHA.116.025957","volume":"135","author":"BR Lindman","year":"2017","unstructured":"Lindman BR (2017) The diabetic heart failure with preserved ejection fraction phenotype. Circulation 135(8):736\u2013740. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025957","journal-title":"Circulation"},{"issue":"5","key":"10600_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K et al (2019) Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art review. J Am Coll Cardiol 73(5):602\u2013611. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.033","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10600_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K van Damman","year":"2014","unstructured":"Damman K, Valente MAE, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35(7):455\u2013469. https:\/\/doi.org\/10.1093\/eurheartj\/eht386","journal-title":"Eur Heart J"},{"issue":"1","key":"10600_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000542633","volume":"15","author":"H Khandait","year":"2025","unstructured":"Khandait H, Sodhi SS, Khandekar N, Bhattad VB (2025) Cardiorenal syndrome in heart failure with preserved ejection fraction: insights into pathophysiology and recent advances. Cardiorenal Med 15(1):41\u201360. https:\/\/doi.org\/10.1159\/000542633","journal-title":"Cardiorenal Med"},{"issue":"9","key":"10600_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","volume":"138","author":"F Zannad","year":"2018","unstructured":"Zannad F, Rossignol P (2018) Cardiorenal syndrome revisited. Circulation 138(9):929\u2013944. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028814","journal-title":"Circulation"},{"issue":"5","key":"10600_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.pcd.2025.07.007","volume":"19","author":"M Saad","year":"2025","unstructured":"Saad M et al (2025) Effects of intensive blood pressure control on cardiovascular outcomes in patients with diabetes: a systematic review and meta-analysis. Prim Care Diabetes 19(5):422\u2013425. https:\/\/doi.org\/10.1016\/j.pcd.2025.07.007","journal-title":"Prim Care Diabetes"},{"issue":"22","key":"10600_CR41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Research Group et al. et al","year":"2015","unstructured":"SPRINT Research Group et al. et al et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103\u20132116. https:\/\/doi.org\/10.1056\/NEJMoa1511939","journal-title":"N Engl J Med"},{"issue":"5","key":"10600_CR42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","volume":"11","author":"WT Ambrosius","year":"2014","unstructured":"Ambrosius WT et al (2014) The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11(5):532\u2013546. https:\/\/doi.org\/10.1177\/1740774514537404","journal-title":"Clin Trials"},{"issue":"24","key":"10600_CR43","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged\u2009\u2265\u200975 years: a randomized clinical trial. JAMA 315(24):2673\u20132682. https:\/\/doi.org\/10.1001\/jama.2016.7050","journal-title":"JAMA"},{"issue":"14","key":"10600_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W et al (2021) Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 385(14):268\u20131279. https:\/\/doi.org\/10.1056\/NEJMoa2111437","journal-title":"N Engl J Med"},{"issue":"12","key":"10600_CR45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/nejmoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi Y et al (2025) Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med 392(12):1155\u20131167. https:\/\/doi.org\/10.1056\/nejmoa2412006","journal-title":"N Engl J Med"},{"issue":"11","key":"10600_CR46","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA (2019) Heart failure with preserved ejection fraction in perspective. Circ Res 124(11):1598\u20131617. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.313572","journal-title":"Circ Res"},{"issue":"43","key":"10600_CR47","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","volume":"37","author":"BA Borlaug","year":"2016","unstructured":"Borlaug BA, Kane GC, Melenovsky V, Olson TP (2016) Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 37(43):3293\u20133302. https:\/\/doi.org\/10.1093\/eurheartj\/ehw241","journal-title":"Eur Heart J"},{"issue":"11","key":"10600_CR48","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","volume":"56","author":"BA Borlaug","year":"2010","unstructured":"Borlaug BA et al (2010) Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56(11):845\u2013854. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.077","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10600_CR49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jchf.2016.03.001","volume":"4","author":"TP Olson","year":"2016","unstructured":"Olson TP, Johnson BD, Borlaug BA (2016) Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 4(6):490\u2013498. https:\/\/doi.org\/10.1016\/j.jchf.2016.03.001","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10600_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10741-025-10504-3","volume":"30","author":"B Pecchia","year":"2025","unstructured":"Pecchia B, Samuel R, Shah V, Newman E, Gibson GT (2025) Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF). Heart Fail Rev 30(4):777\u2013789. https:\/\/doi.org\/10.1007\/s10741-025-10504-3","journal-title":"Heart Fail Rev"},{"key":"10600_CR51","doi-asserted-by":"publisher","unstructured":"Del MG, Buono et al (2019) Exercise intolerance in patients with heart failure: JACC State-of-the-Art review. J Am Coll Cardiol 73:2209\u20132225. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.072","DOI":"10.1016\/j.jacc.2019.01.072"},{"key":"10600_CR52","doi-asserted-by":"publisher","unstructured":"Reddy YNV, Olson TP, Obokata M, Melenovsky V, Borlaug BA (2018) Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. JACC Heart Fail 6(8):665\u2013675. https:\/\/doi.org\/10.1016\/j.jchf.2018.03.003","DOI":"10.1016\/j.jchf.2018.03.003"},{"issue":"15","key":"10600_CR53","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jacc.2015.07.067","volume":"66","author":"BA Borlaug","year":"2015","unstructured":"Borlaug BA, Koepp KE, Melenovsky V (2015) Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 66(15):1672\u20131682. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.067","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10600_CR54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrd2466","volume":"7","author":"JO Lundberg","year":"2008","unstructured":"Lundberg JO, Weitzberg E, Gladwin MT (2008) The nitrate\u2013nitrite\u2013nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7(2):156\u2013167. https:\/\/doi.org\/10.1038\/nrd2466","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10600_CR55","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","volume":"59","author":"S Schwartzenberg","year":"2012","unstructured":"Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59(5):442\u2013451. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.062","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10600_CR56","doi-asserted-by":"publisher","first-page":"e89620","DOI":"10.1172\/jci.insight.89620","volume":"1","author":"MA Simon","year":"2016","unstructured":"Simon MA et al (2016) Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight 1(18):e89620. https:\/\/doi.org\/10.1172\/jci.insight.89620","journal-title":"JCI Insight"},{"issue":"4","key":"10600_CR57","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/ehf2.13952","volume":"9","author":"P Codina","year":"2022","unstructured":"Codina P et al (2022) Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail 9(4):2170\u20132180. https:\/\/doi.org\/10.1002\/ehf2.13952","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10600_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccl.2022.06.004","volume":"40","author":"AE Peters","year":"2022","unstructured":"Peters AE, DeVore AD (2022) Pharmacologic therapy for heart failure with preserved ejection fraction. Cardiol Clin 40(4):473\u2013489. https:\/\/doi.org\/10.1016\/j.ccl.2022.06.004","journal-title":"Cardiol Clin"},{"issue":"2","key":"10600_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11897-024-00643-3","volume":"21","author":"JJ Cuthbert","year":"2024","unstructured":"Cuthbert JJ, Clark AL (2024) Diuretic treatment in patients with heart failure: current evidence and future directions \u2013 Part I: Loop Diuretics. Curr Heart Fail Rep 21(2):101\u2013114. https:\/\/doi.org\/10.1007\/s11897-024-00643-3","journal-title":"Curr Heart Fail Rep"},{"issue":"1","key":"10600_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA et al (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation 131(1):34\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013255","journal-title":"Circulation"},{"issue":"5","key":"10600_CR61","doi-asserted-by":"publisher","first-page":"CD003825","DOI":"10.1002\/14651858.CD003825.pub4","volume":"2015","author":"VM Musini","year":"2015","unstructured":"Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD (2015) Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015(5):CD003825. https:\/\/doi.org\/10.1002\/14651858.CD003825.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"10600_CR62","doi-asserted-by":"publisher","unstructured":"Malha L, Mann SJ (2016) Loop diuretics in the treatment of hypertension. Curr Hypertens Rep 18(4). https:\/\/doi.org\/10.1007\/s11906-016-0636-7","DOI":"10.1007\/s11906-016-0636-7"},{"issue":"2","key":"10600_CR63","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1136\/hrt.72.2_suppl.s40","volume":"72","author":"DC Brater","year":"1994","unstructured":"Brater DC (1994) Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 72(2):S40\u2013S43. https:\/\/doi.org\/10.1136\/hrt.72.2_suppl.s40","journal-title":"Br Heart J"},{"issue":"2","key":"10600_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W et al (2019) The use of diuretics in heart failure with congestion \u2014 a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail 21(2):137\u2013155. https:\/\/doi.org\/10.1002\/ejhf.1369","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10600_CR65","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H et al (2019) JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart Failure\u3000\u2015 digest version \u2015. Circ J 83(10):2084\u20132184. https:\/\/doi.org\/10.1253\/circj.CJ-19-0342","journal-title":"Circ J"},{"issue":"2","key":"10600_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.cir.0000021601.49664.2a","volume":"106","author":"K Wachtell","year":"2002","unstructured":"Wachtell K et al (2002) Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 106(2):227\u2013232. https:\/\/doi.org\/10.1161\/01.cir.0000021601.49664.2a","journal-title":"Circulation"},{"issue":"5","key":"10600_CR67","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","volume":"54","author":"RH Fagard","year":"2009","unstructured":"Fagard RH, Celis H, Thijs L, Wouters S (2009) Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 54(5):1084\u20131091. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.136655","journal-title":"Hypertension"},{"issue":"9","key":"10600_CR68","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/HYPERTENSIONAHA.122.20732","volume":"80","author":"Y Deng","year":"2023","unstructured":"Deng Y et al (2023) Intensive blood pressure lowering improves left ventricular hypertrophy in older patients with hypertension: the STEP Trial. Hypertension 80(9):1834\u20131842. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.20732","journal-title":"Hypertension"},{"issue":"9","key":"10600_CR69","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/hc0902.104599","volume":"105","author":"K Wachtell","year":"2002","unstructured":"Wachtell K et al (2002) Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 105(9):1071\u20131076. https:\/\/doi.org\/10.1161\/hc0902.104599","journal-title":"Circulation"},{"issue":"3","key":"10600_CR70","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1253\/circj.CJ-17-1019","volume":"82","author":"M Nakabachi","year":"2018","unstructured":"Nakabachi M et al (2018) Left ventricular mass influences relationship between filling pressure and early-diastolic ratio of inflow velocity to mitral annular velocity (E\/e\u2019). Circ J Off J Jpn Circ Soc 82(3):732\u2013738. https:\/\/doi.org\/10.1253\/circj.CJ-17-1019","journal-title":"Circ J Off J Jpn Circ Soc"},{"issue":"4","key":"10600_CR71","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11906-001-0092-9","volume":"3","author":"N Winer","year":"2001","unstructured":"Winer N, Weber MA, Sowers JR (2001) The effect of antihypertensive drugs on vascular compliance. Curr Hypertens Rep 3(4):297\u2013304. https:\/\/doi.org\/10.1007\/s11906-001-0092-9","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"10600_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1524-6175.2006.05342.x","volume":"8","author":"CA Bellido","year":"2007","unstructured":"Bellido CA et al (2007) Continuous improvement of arterial compliance beyond blood pressure decrease after 5 years of antihypertensive treatmente. J Clin Hypertens 8(8):555\u2013560. https:\/\/doi.org\/10.1111\/j.1524-6175.2006.05342.x","journal-title":"J Clin Hypertens"},{"key":"10600_CR73","doi-asserted-by":"publisher","unstructured":"Cameron JD, Rajkumar C, Kingwell BA, Jennings GL, Dart AM (1999) Higher systemic arterial compliance is associated with greater exercise time and lower blood pressure in a young older population. J Am Geriatr Soc 47(6):653\u2013656. https:\/\/doi.org\/10.1111\/j.1532-5415.1999.tb01585.x","DOI":"10.1111\/j.1532-5415.1999.tb01585.x"},{"issue":"15","key":"10600_CR74","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"10600_CR75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2024.09.003","volume":"131","author":"X Liu","year":"2025","unstructured":"Liu X et al (2025) Association between trajectory of systolic blood pressure and outcomes in heart failure patients with preserved ejection fraction (HFpEF). Eur J Intern Med 131:89\u201397. https:\/\/doi.org\/10.1016\/j.ejim.2024.09.003","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10600_CR76","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/HJH.0000000000002807","volume":"39","author":"P Huang","year":"2021","unstructured":"Huang P et al (2021) Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. J Hypertens 39(7):1378. https:\/\/doi.org\/10.1097\/HJH.0000000000002807","journal-title":"J Hypertens"},{"issue":"7","key":"10600_CR77","doi-asserted-by":"publisher","first-page":"e022765","DOI":"10.1161\/JAHA.121.022765","volume":"11","author":"R Huang","year":"2022","unstructured":"Huang R et al (2022) Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction. J Am Heart Assoc 11(7):e022765. https:\/\/doi.org\/10.1161\/JAHA.121.022765","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"10600_CR78","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","volume":"75","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S et al (2020) Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan. J Am Coll Cardiol 75(14):1644\u20131656. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.009","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10600_CR79","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.cardfail.2008.05.002","volume":"14","author":"R Krittayaphong","year":"2008","unstructured":"Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S (2008) Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail 14(8):687\u2013694. https:\/\/doi.org\/10.1016\/j.cardfail.2008.05.002","journal-title":"J Card Fail"},{"issue":"2","key":"10600_CR80","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","volume":"77","author":"K Suzuki","year":"2021","unstructured":"Suzuki K et al (2021) Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction. Hypertension 77(2):546\u2013556. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16277","journal-title":"Hypertension"},{"key":"10600_CR81","doi-asserted-by":"publisher","unstructured":"Matsumoto C, Nagai M, Shinohara K, Morikawa N, Kai H, Arima H (2025) Systolic blood pressure lower than 130 mmhg in heart failure with preserved ejection fraction: a systematic review and meta-analysis of clinical outcomes. Hypertens Res 1\u201314. https:\/\/doi.org\/10.1038\/s41440-025-02240-w","DOI":"10.1038\/s41440-025-02240-w"},{"key":"10600_CR82","doi-asserted-by":"publisher","unstructured":"Anker MS et al (2025) Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial. Glob Cardiol 3(3). https:\/\/doi.org\/10.4081\/cardio.2025.78","DOI":"10.4081\/cardio.2025.78"},{"key":"10600_CR83","doi-asserted-by":"publisher","unstructured":"Pitt B, Vaidya A (May 2025) Mineralocorticoid receptor antagonist use in hypertension to prevent heart failure. JACC Heart Fail 102452. https:\/\/doi.org\/10.1016\/j.jchf.2025.02.021","DOI":"10.1016\/j.jchf.2025.02.021"},{"key":"10600_CR84","doi-asserted-by":"publisher","unstructured":"Chang J, Ambrosy AP, Vardeny O, Van Spall HGC, Mentz RJ, Sauer AJ (2024) Mineralocorticoid antagonism in heart failure. JACC: Heart Failure 12(12):1979\u20131993. https:\/\/doi.org\/10.1016\/j.jchf.2024.08.007","DOI":"10.1016\/j.jchf.2024.08.007"},{"issue":"14","key":"10600_CR85","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1093\/eurjpc\/zwac171","volume":"29","author":"MS Arshad","year":"2022","unstructured":"Arshad MS et al (2022) Effect of mineralocorticoid receptor antagonist at baseline on the efficacy of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol 29(14):e334\u2013e337. https:\/\/doi.org\/10.1093\/eurjpc\/zwac171","journal-title":"Eur J Prev Cardiol"},{"key":"10600_CR86","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/VHRM.S170141","volume":"14","author":"M Fernet","year":"2018","unstructured":"Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E (2018) Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. Vasc Health Risk Manag 14:233\u2013246. https:\/\/doi.org\/10.2147\/VHRM.S170141","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"10600_CR87","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41371-023-00891-1","volume":"38","author":"SS Shah","year":"2024","unstructured":"Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J (2024) Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. J Hum Hypertens 38(5):383\u2013392. https:\/\/doi.org\/10.1038\/s41371-023-00891-1","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10600_CR88","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ejhf.1060","volume":"20","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S et al (2018) Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. Eur J Heart Fail 20(3):483\u2013490. https:\/\/doi.org\/10.1002\/ejhf.1060","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10600_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial. JAMA 309(8):781\u2013791. https:\/\/doi.org\/10.1001\/jama.2013.905","journal-title":"JAMA"},{"key":"10600_CR90","doi-asserted-by":"publisher","unstructured":"Solomon SD et al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction, N. Engl. J. Med., vol. 391, no. 16, pp. 1475\u20131485, Oct. https:\/\/doi.org\/10.1056\/NEJMoa2407107","DOI":"10.1056\/NEJMoa2407107"},{"issue":"4","key":"10600_CR91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","volume":"71","author":"LB Arendse","year":"2019","unstructured":"Arendse LB et al (2019) novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev 71(4):539\u2013570. https:\/\/doi.org\/10.1124\/pr.118.017129","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10600_CR92","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR (2018) Role of RAAS activation in promoting cardiovascular fibrosis and stiffness. Hypertension 72(3):537\u2013548. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11065","journal-title":"Hypertension"},{"issue":"6","key":"10600_CR93","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40256-023-00605-5","volume":"23","author":"LA Alcocer","year":"2023","unstructured":"Alcocer LA et al (2023) The pivotal role of angiotensin-Converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: A critical appraisal and comparison of international guidelines. Am J Cardiovasc Drugs 23(6):663\u2013682. https:\/\/doi.org\/10.1007\/s40256-023-00605-5","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10600_CR94","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJMoa0805450","volume":"23","author":"LA Alcocer","year":"2023","unstructured":"Massie BM et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467. https:\/\/doi.org\/10.1056\/NEJMoa0805450","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9386","key":"10600_CR95","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S et al (Sep. 2003) Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362(9386):777\u2013781. https:\/\/doi.org\/10.1016\/S0140-6736(03)14285-7","journal-title":"Lancet"},{"issue":"19","key":"10600_CR96","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland JGF (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345. https:\/\/doi.org\/10.1093\/eurheartj\/ehl250","journal-title":"Eur Heart J"},{"issue":"11","key":"10600_CR97","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s00392-020-01632-x","volume":"109","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP et al (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol Off J Ger Card Soc 109(11):1358\u20131365. https:\/\/doi.org\/10.1007\/s00392-020-01632-x","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"issue":"17","key":"10600_CR98","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"L Yuliya","year":"2017","unstructured":"Yuliya L, Petter B, Udell JA, Lovshin JA, Cherney DZ (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications and summary of clinical trials. Circulation 136(17):1643\u20131658. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030012","journal-title":"Circulation"},{"issue":"18","key":"10600_CR99","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.053709","volume":"143","author":"K Kario","year":"2021","unstructured":"Kario K, Ferdinand KC, Vongpatanasin W (2021) Are SGLT2 inhibitors new hypertension drugs? Circulation 143(18):1750\u20131753. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053709","journal-title":"Circulation"},{"issue":"4","key":"10600_CR100","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","volume":"75","author":"CS Wilcox","year":"2020","unstructured":"Wilcox CS (2020) Antihypertensive and renal mechanisms of SGLT2 (Sodium-Glucose linked transporter 2) inhibitors. Hypertension 75(4):894\u2013901. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.11684","journal-title":"Hypertension"},{"issue":"1","key":"10600_CR101","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","volume":"11","author":"S Selvaraj","year":"2023","unstructured":"Selvaraj S et al (2023) Blood pressure and Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC Heart Fail 11(1):76\u201389. https:\/\/doi.org\/10.1016\/j.jchf.2022.09.002","journal-title":"JACC Heart Fail"},{"key":"10600_CR102","doi-asserted-by":"publisher","unstructured":"Heidenreich PA et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 145(18). https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"11","key":"10600_CR103","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME et al (2021) The SGLT2 inhibitor Dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954\u20131960. https:\/\/doi.org\/10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"issue":"3","key":"10600_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J et al (2022) Empagliflozin, health Status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 145(3):184\u2013193. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057812","journal-title":"Circulation"},{"key":"10600_CR105","doi-asserted-by":"publisher","unstructured":"Usman MS et al (2024) The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis. Glob Cardiol 2(2). https:\/\/doi.org\/10.4081\/cardio.2024.35","DOI":"10.4081\/cardio.2024.35"},{"issue":"12","key":"10600_CR106","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"issue":"16","key":"10600_CR107","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD et al (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"10600_CR108","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijcard.2018.06.060","volume":"281","author":"M Gori","year":"2019","unstructured":"Gori M, D\u2019Elia E, Senni M (2019) Sacubitril\/valsartan therapeutic strategy in hfpef: clinical insights and perspectives. Int J Cardiol 281:158\u2013165. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.060","journal-title":"Int J Cardiol"},{"key":"10600_CR109","doi-asserted-by":"publisher","unstructured":"Jackson AM et al (2021) Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 42(36):3741\u20133752. https:\/\/doi.org\/10.1093\/eurheartj\/ehab499","DOI":"10.1093\/eurheartj\/ehab499"},{"issue":"5","key":"10600_CR110","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","volume":"8","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW et al (2020) Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC: Heart Fail 8(5):372\u2013381. https:\/\/doi.org\/10.1016\/j.jchf.2020.03.002","journal-title":"JACC: Heart Fail"},{"issue":"5","key":"10600_CR111","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","volume":"141","author":"JJV McMurray","year":"2020","unstructured":"McMurray JJV et al (2020) Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from paragON-HF. Circulation 141(5):338\u2013351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044491","journal-title":"Circulation"},{"issue":"5","key":"10600_CR112","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD et al (2020) Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141(5):352\u2013361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044586","journal-title":"Circulation"},{"issue":"3","key":"10600_CR113","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","volume":"6","author":"M Vaduganathan","year":"2021","unstructured":"Vaduganathan M et al (2021) Applicability of US food and drug administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: the get with the guidelines-heart failure (GWTG-HF) registry. JAMA Cardiol 6(3):267\u2013275. https:\/\/doi.org\/10.1001\/jamacardio.2020.5864","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10600_CR114","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ et al (2018) Medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 72(4):351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10600_CR115","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jchf.2018.11.011","volume":"7","author":"PA Peri-Okonny","year":"2019","unstructured":"Peri-Okonny PA et al (2019) Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail 7(4):350\u2013358. https:\/\/doi.org\/10.1016\/j.jchf.2018.11.011","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10600_CR116","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/CIRCRESAHA.122.319989","volume":"130","author":"KP Patel","year":"2022","unstructured":"Patel KP, Katsurada K, Zheng H (2022) Cardiorenal syndrome: the role of neural connections between the heart and the kidneys. Circ Res 130(10):1601\u20131617. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.319989","journal-title":"Circ Res"},{"issue":"SupplementE","key":"10600_CR117","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1093\/eurheartjsupp\/suac030","volume":"24","author":"E Gronda","year":"2022","unstructured":"Gronda E, Dusi V, D\u2019Elia E, Iacoviello M, Benvenuto E, Vanoli E (2022) Sympathetic activation in heart failure. Eur Heart J Suppl 24(SupplementE):E4\u2013E11. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac030","journal-title":"Eur Heart J Suppl"},{"key":"10600_CR118","doi-asserted-by":"publisher","unstructured":"Sata Y, Head GA, Denton K, May CN, Schlaich MP (2018) Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med 5:82. https:\/\/doi.org\/10.3389\/fmed.2018.00082","DOI":"10.3389\/fmed.2018.00082"},{"issue":"2","key":"10600_CR119","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1152\/ajpregu.00351.2014","volume":"308","author":"UC Kopp","year":"2015","unstructured":"Kopp UC (2015) Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol 308(2):R79\u201395. https:\/\/doi.org\/10.1152\/ajpregu.00351.2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"10600_CR120","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10741-024-10463-1","volume":"30","author":"H Jiang","year":"2025","unstructured":"Jiang H et al (2025) The road to renal denervation for hypertension and beyond (HF): two decades of failed, succeeded, and to be determined. Heart Fail Rev 30(2):293\u2013314. https:\/\/doi.org\/10.1007\/s10741-024-10463-1","journal-title":"Heart Fail Rev"},{"key":"10600_CR121","doi-asserted-by":"publisher","unstructured":"Arshad MS, Kittipibul V, Fudim M (2025) Sympathetic nervous system in heart failure: targets for treatments. Curr Hypertens Rep 27(1). https:\/\/doi.org\/10.1007\/s11906-025-01337-4","DOI":"10.1007\/s11906-025-01337-4"},{"issue":"3","key":"10600_CR122","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/HYPERTENSIONAHA.120.16054","volume":"78","author":"LC Booth","year":"2021","unstructured":"Booth LC et al (2021) Renal, cardiac, and autonomic effects of catheter-based renal denervation in ovine heart failure. Hypertension 78(3):706\u2013715. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16054","journal-title":"Hypertension"},{"issue":"4","key":"10600_CR123","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41440-024-01583-0","volume":"47","author":"Z Honetschl\u00e4gerov\u00e1","year":"2024","unstructured":"Honetschl\u00e4gerov\u00e1 Z et al (2024) Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 Transgenic hypertensive rats with volume overload induced using aorto-caval fistula. Hypertens Res 47(4):998\u20131016. https:\/\/doi.org\/10.1038\/s41440-024-01583-0","journal-title":"Hypertens Res"},{"issue":"12","key":"10600_CR124","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3390\/jcm14124115","volume":"14","author":"D Jamil","year":"2025","unstructured":"Jamil D et al (2025) The role of renal denervation in HFpEF. J Clin Med 14(12):4115. https:\/\/doi.org\/10.3390\/jcm14124115","journal-title":"J Clin Med"},{"key":"10600_CR125","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.jacc.2013.10.073","volume":"63","author":"SH Schirmer","year":"2014","unstructured":"Schirmer SH et al (2014) Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 63:1916\u20131923. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.073","journal-title":"J Am Coll Cardiol"},{"key":"10600_CR126","doi-asserted-by":"publisher","unstructured":"Dhakal P, Liu K, KozmanJr H, Villarreal D (2015) Renal denervation in heart failure: A new therapeutic paradigm. Clin Med Insights Cardiol 9s1 CMC.S18754. https:\/\/doi.org\/10.4137\/CMC.S18754","DOI":"10.4137\/CMC.S18754"},{"key":"10600_CR127","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3389\/fphys.2019.01625","volume":"10","author":"W-J Chen","year":"2019","unstructured":"Chen W-J et al (2019) The impact of renal denervation on the progression of heart failure in a canine model induced by right ventricular rapid pacing. Front Physiol 10:1625. https:\/\/doi.org\/10.3389\/fphys.2019.01625","journal-title":"Front Physiol"},{"issue":"4","key":"10600_CR128","doi-asserted-by":"publisher","first-page":"e032646","DOI":"10.1161\/JAHA.123.032646","volume":"13","author":"JE Doiron","year":"2024","unstructured":"Doiron JE et al (2024) Early renal denervation attenuates cardiac dysfunction in heart failure with preserved ejection fraction. J Am Heart Assoc 13(4):e032646. https:\/\/doi.org\/10.1161\/JAHA.123.032646","journal-title":"J Am Heart Assoc"},{"issue":"33","key":"10600_CR129","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/eurheartj\/ehu093","volume":"35","author":"F Mahfoud","year":"2014","unstructured":"Mahfoud F et al (2014) Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 35(33):2224\u20132231b. https:\/\/doi.org\/10.1093\/eurheartj\/ehu093","journal-title":"Eur Heart J"},{"issue":"10137","key":"10600_CR130","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE et al (Jun. 2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet Lond Engl 391(10137):2346\u20132355. https:\/\/doi.org\/10.1016\/S0140-6736(18)30951-6","journal-title":"Lancet Lond Engl"},{"issue":"10234","key":"10600_CR131","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M et al (May 2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet Lond Engl 395(10234):1444\u20131451. https:\/\/doi.org\/10.1016\/S0140-6736(20)30554-7","journal-title":"Lancet Lond Engl"},{"issue":"10293","key":"10600_CR132","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial, Lancet Lond. Engl., vol. 397, no. 10293, pp. 2476\u20132486, Jun. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1","journal-title":"Lancet"},{"issue":"16","key":"10600_CR133","doi-asserted-by":"publisher","first-page":"e034910","DOI":"10.1161\/JAHA.124.034910","volume":"13","author":"SH Mufarrih","year":"2024","unstructured":"Mufarrih SH et al (2024) Randomized trials of renal denervation for uncontrolled hypertension: an updated meta-analysis. J Am Heart Assoc 13(16):e034910. https:\/\/doi.org\/10.1161\/JAHA.124.034910","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10600_CR134","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","volume":"162","author":"JE Davies","year":"2013","unstructured":"Davies JE et al (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 162(3):189\u2013192. https:\/\/doi.org\/10.1016\/j.ijcard.2012.09.019","journal-title":"Int J Cardiol"},{"issue":"9","key":"10600_CR135","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cardfail.2017.06.004","volume":"23","author":"I Hopper","year":"2017","unstructured":"Hopper I et al (2017) Sympathetic response and outcomes following renal denervation in patients with chronic heart failure: 12-month outcomes from the Symplicity HF feasibility study. J Card Fail 23(9):702\u2013707. https:\/\/doi.org\/10.1016\/j.cardfail.2017.06.004","journal-title":"J Card Fail"},{"issue":"4","key":"10600_CR136","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1002\/ccd.26475","volume":"89","author":"W Chen","year":"2017","unstructured":"Chen W et al (2017) Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: a prospective, randomized, controlled, pilot study. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 89(4):E153\u2013E161. https:\/\/doi.org\/10.1002\/ccd.26475","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"issue":"5","key":"10600_CR137","doi-asserted-by":"publisher","first-page":"503","DOI":"10.5603\/CJ.a2018.0028","volume":"26","author":"J-Q Gao","year":"2019","unstructured":"Gao J-Q, Yang W, Liu Z-J (2019) Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial. Cardiol J 26(5):503\u2013510. https:\/\/doi.org\/10.5603\/CJ.a2018.0028","journal-title":"Cardiol J"},{"issue":"6","key":"10600_CR138","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ejhf.502","volume":"18","author":"HC Patel","year":"2016","unstructured":"Patel HC et al (2016) Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail 18(6):703\u2013712. https:\/\/doi.org\/10.1002\/ejhf.502","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10600_CR139","doi-asserted-by":"publisher","first-page":"e007421","DOI":"10.1161\/CIRCHEARTFAILURE.120.007421","volume":"14","author":"K-P Kresoja","year":"2021","unstructured":"Kresoja K-P et al (2021) Renal sympathetic denervation in patients with heart failure with preserved ejection fraction. Circ Heart Fail 14(3):e007421. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007421","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10600_CR140","doi-asserted-by":"publisher","first-page":"e008301","DOI":"10.1161\/CIRCHEARTFAILURE.121.008301","volume":"14","author":"M Fudim","year":"2021","unstructured":"Fudim M, Sobotka PA, Piccini JP, Patel MR (2021) Renal denervation for patients with heart failure: making a full circle. Circ Heart Fail 14(3):e008301. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008301","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10600_CR141","doi-asserted-by":"publisher","first-page":"e010543","DOI":"10.1161\/CIRCHEARTFAILURE.123.010543","volume":"16","author":"K-P Rommel","year":"2023","unstructured":"Rommel K-P et al (2023) Modulation of pulsatile left ventricular afterload by renal denervation in heart failure with preserved ejection fraction. Circ Heart Fail 16(10):e010543. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010543","journal-title":"Circ Heart Fail"},{"key":"10600_CR142","doi-asserted-by":"publisher","unstructured":"Vogt A et al (2024) Left ventricular structure and function following renal sympathetic denervation in patients with HFpEF: an echocardiographic 9-year long-term follow-up. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2024.1408547","DOI":"10.3389\/fcvm.2024.1408547"},{"key":"10600_CR143","unstructured":"Universit\u00e4t des, Saarlandes A, Prospective M, Randomized B (2022) Sham-controlled, Feasibility study of renal denervation in patients with chronic heart failure, clinicaltrials.gov, Clinical trial registration NCT04947670, Nov. Accessed: Jul. 22, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04947670"},{"issue":"4","key":"10600_CR144","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10741-025-10489-z","volume":"30","author":"F Koppe-Schmei\u00dfer","year":"2025","unstructured":"Koppe-Schmei\u00dfer F, Fengler K, Kresoja K-P, Lurz P, Rommel K-P (2025) Renal denervation in the setting of heart failure. Heart Fail Rev 30(4):707\u2013714. https:\/\/doi.org\/10.1007\/s10741-025-10489-z","journal-title":"Heart Fail Rev"},{"key":"10600_CR145","unstructured":"Fengler K (2024) Renal denervation to treat heart failure with preserved ejection fraction - a pilot trial, clinicaltrials.gov, Clinical trial registration NCT05030987. Accessed: Jul. 22, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05030987"},{"key":"10600_CR146","unstructured":"Xie X (2024) The first affiliated hospital of xinjiang medical university, clinicaltrials.gov, Clinical trial registration NCT05715697, Jan. Accessed: Jul. 22, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05715697"},{"key":"10600_CR147","unstructured":"Vascular M (2025) Global SYMPLICITY Registry (GSR) denervation findings in real world (define), clinicaltrials.gov, clinical trial registration NCT01534299, Apr. Accessed: Nov. 10, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT01534299"},{"issue":"10","key":"10600_CR148","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00392-023-02325-x","volume":"113","author":"F Mahfoud","year":"2024","unstructured":"Mahfoud F et al (2024) Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the global paradise system registry study design. Clin Res Cardiol Off J Ger Card Soc 113(10):1375\u20131383. https:\/\/doi.org\/10.1007\/s00392-023-02325-x","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"key":"10600_CR149","doi-asserted-by":"publisher","unstructured":"Mancia G et al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA), J. Hypertens 41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480","DOI":"10.1097\/HJH.0000000000003480"},{"issue":"38","key":"10600_CR150","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW et al (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J 45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178","journal-title":"Eur Heart J"},{"key":"10600_CR151","doi-asserted-by":"publisher","unstructured":"Camafort M, Red\u00f3n J, Pyun WB, Coca A (2020) Intensive blood pressure lowering: a practical review. Clin Hypertens 26(1):21. https:\/\/doi.org\/10.1186\/s40885-020-00153-z","DOI":"10.1186\/s40885-020-00153-z"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10600-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:03:05Z","timestamp":1773079385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10600"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10600-y","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"P.L. has received institutional fees and research grants from Abbott Vascular, Edwards Lifesciences, and ReCor; honoraria from Edwards Lifesciences, Abbott Medical, Innoventric, ReCor, and Boehringer Ingelheim; and has stock options with Innoventric. K.P.R. has received consultant fees from Edwards Lifesciences. M.S.K. has participated in a data-safety monitoring board or advisory board for Bayer and reports consulting fees from Bayer, Novartis, and Boehringer Ingelheim. S.B. serves on advisory boards for Abbott Vascular, Boston Scientific, Biotronik, Amgen, Pfizer, Merck, Shockwave, ReCor, Inari, and Imperative Care. H.D.A. reports consulting for ReCor, Medtronic, and Silk Road Medical. J.A.G. received funding from the Department of Veterans Affairs outside the submitted work. M.F. was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant and\/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, BMS, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FlowMod, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vifor Pharma, Vironix, Viscardia, and Zoll. All other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}